Olanzapine: Pharmacokinetic and pharmacodynamic profile

Clinical Pharmacokinetics

Volumn 37, Issue 3, 1999, Pages 177-193

  Callaghan, John T ^a,b   Bergstrom, Richard F ^a,b   Ptak, Louis R ^a,c   Beasley, Charles M ^a,d  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Trilogy Consulting Corporation   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; AMINOPHYLLINE; BIPERIDEN; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OROSOMUCOID; PROLACTIN; TOBACCO SMOKE;

ADULT; AGED; AREA UNDER THE CURVE; CAR DRIVING; CLINICAL TRIAL; COGNITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR ACTIVITY; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; PIRENZEPINE; TIME FACTORS;

EID: 0032844187     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937030-00001     Document Type: Review

References (56)

1. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine, and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2: 281-93
2. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven, 1992: 241-51
3. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven, 1992: 1-13
4. Fuller A, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY 170053) an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992; 77 (1): 87-93
5. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14 (2): 87-96
6. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995; 120: 67-74
7. Beasley CM. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry Monogr 1997; 15: 16-8
8. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154(9): 1248-54
9. Bergstrom RF, Callaghan JT, CErimele BJ, et al. Biopharmaceutics integrated: summary volume. Lilly Laboratory for Clinical Research. Eh Lilly and Co., 155. (Data on file)
10. Bergstrom RF, Callaghan JT, Cerimele BJ, et al. Pharmacokinetics of olanzapine in elderly and young. Pharm Res 1995; 12 Suppl. 9: S-358
11. Nyhart Jr EH, Cerimele BJ, Kassahun K, et al. Olanzapine: an initial assessment of the bioequivalence of capsules and tablet formulations [abstract no. 8355]. 10th Annual Meeting and Exposition, American Association of Pharmaceutical Scientists; 1995 Nov 5-9; Miami Beach (FL)
12. Bergstrom RF, Cerimele BJ, et al. Olazapine in subjects with and without renal failure. Lilly Laboratory for Clinical Research. Eli Lilly und Co., 1996. (Data on file)
13. Callaghan JT, Bergstrom RF, Cerimele BJ, et al. Oral olanzapine: safety and pharmacokinetic study in elderly. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1995. (Data on file)
14. Thomasson HR, Callaghan JT, Bergstrom RF, et al. Oral olanzapine: safety and pharmacokineticstudy in subjects with cirrhosis. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1996. (Data on file)
15. Kisicki JC, Bergstrom RF, Cerimele RJ, et al. Olanzapine: bioequivalence of capsule and tablet formulations. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1995. (Data on file)
16. Henry DP, Nybart Jr EH. LY 170 053: dose proportionality and effect of feeding on bioavailability. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1995. (Data on file)
17. Bergstrom RF, Cerimele BJ, Callaghan JT, et al. Oral olanzapine: safety and pharmacokinetic study in Asians. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1997. (Data on file)
18. Malituz EL, Cerimele BJ, Ptak L. Olanzapine: safety and pharmacokinetic studies on patients with cirrhosis - olanzapine excretion addendum. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1997. (Data on file)
19. Kassahun K, Mattiuz E, Nyhart Jr E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997; 25 (1): 81-93
20. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658-66
21. Kussahun K. Olanzapine, N-desmethyl olanzapine and 10-N-glucuronide of olanzapine in plasma from patients on olanzapine. Indianapolis: Eli Lilly and Co., 1995 (Data on file)
22. Patel BR, Kurtz DL. Population pharmacokinetic analyses of olanzapine. Indianapolis: Eli Lilly and Co., 1995 (Data on file)
23. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1906; 41: 181-6
24. Callaghan JT, Cerimele BJ, Kussahun KJ, et al. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997; 37 (10): 971-8
25. Maya JF, Callaghan JT, Bergstrom RF, et al. Olanzapine and warfarin drug interaction [abstract]. Clin Pharmacol Ther 1997; 61 (2): 182
26. Macias WL, Bergstrom RF, Cerimele BJ, et al. Lack of an effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 1998; 18 (6): 1237-48
27. Demmole D, Onkelinx C, Muller-Oerlinghausen B. Interaction between olanzapine and lithium in healthy male volunteers [abstract]. Therapie 1995; 50 Suppl.: 486
28. Gossen D, de Suray J-M, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. Indianapolis: Eli Lilly and Co., 1998. (Data on file)
29. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45 (6): 1211-4
30. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39 (2); 151-9
31. MäenpääJ, Wrighton S, Bergstrom R, Bergstrom R, et al. Pharmacokinetic and pharmacodynamic interactions between fluvoxamine and olanzapine [abstract]. Clin Pharmacol Ther 1997; 61 (2): 225
32. Moreland TA, Park BK, Rylance GW. Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6-beta-hydroxycortisol excretion and plasma gamma-glutamyltransferase activity. Br J Clin Pharmacol 1982; 14 (6): 861-5
33. Patsalos PN, Duncan JS. Anticpileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9 (3): 156-84
34. Choonara I, Parker AC, Preston T, et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998; 45 (2): 176-8
35. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms. Eur J Clin Pharmacol 1998 Oct; 54 (8): 639-43
36. Boobis AR, Davies DS. Human cylochromes P-450. Xenobiotica 1984; 14 (1-2): 151-85
37. Kalow W, Tang BK. Caffeine as a metabolite probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49 (1): 44-8
38. Sesardic D, Boobis AR, Edwards RJ, et al. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26 (4): 363-72
39. Callaghan JT, Bergstrom RF, Cerimele BJ, et al. Olanzapine: bioavailability with cimetidine, antacid and charcoal. Lilly Laboratory for Clinical Research. Eli Lilly and Co. (Data on file)
40. Oliver S, Wesnes K, Beuzen J-N. Olanzapine healthy elderly cognition and psychomotor study. Indianapolis; Eli Lilly and Co., 1994 (Data on file)
41. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124: 148-53
42. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16 (1): 1-7
43. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993; 110: 365-7
44. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152 (10): 1444-9
45. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placcbo and haloperidol on serum prolactin concentrations. Schizophrenia Res 1997; 26: 41-54
46. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17 (5): 407-18
47. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154 (4): 457-65
48. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14 (2): 111-23
49. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998; 18 (1): 41-9
50. Martin J, Gomez JC, Garcia-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997; 58 (11): 479-83
51. Beasley Jr CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo; results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-67
52. American Psychiatric Association Task Force on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 3rd rev ed. Washington, DC: APA Press, 1987
53. HGAD Study Team. Olanzapine (LY170053) versus placebo and haloperidol in the treatment of schizophrenia. Indianapolis: Eli Lilly and Co., 1995. (Data on file)
54. Simpson GM. Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212 Suppl.: 11-9
55. Barnes TR. A rating scale for drug-induced akathesia. Br J Psychiatry 1989; 154: 672-6
56. HGAD Study Team. Foxrd-dose olanzapine versus placebo in the treatment of schizophrenia. Indianapolis: Eli Lilly and Co., 1995. (Data on file)